Thank you, Bernard. Good day, everyone, and thank you for joining us. With me today from Orphazyme are Anders Vadsholt, Interim Chief Executive Officer and Chief Financial Officer, Thomas Blaettler, Chief Medical Officer, and Molly Painter, President of Orphazyme US. The slides for this call are available for download on the investors section of our website. Please note that the Q&A will take place at the end of the presentation via conference call. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements. The forward-looking statements are subject to a number of risks, uncertainties and assumptions. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factors or combination of factors may cause actual results to differ materially from those contained in or implied by any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our views change. Now, I'll turn the call over to Anders. Thank you, Molly. Welcome, and everyone, thank you for joining us. On today's call, I'll be making the introduction remarks. Molly Painter will review our commercialization strategy, and then I'll review our financials. We'll move into Q&A, where Thomas Blaettler will also be available for questions. On the slide, as you may have read yesterday, we announced very exciting news for Orphazyme. We appointed Christophe Bourdon as our new Chief Executive Officer. He will officially begin his role on April 1st to give him and his family enough time to relocate to Copenhagen from the U.S. Christophe is a global recognized leader with 25 years of experience in building successful, diverse, cross-functional teams in three continents. Christophe is the ideal Chief Executive Officer for us as he shares our commitment to delivering therapies to patients, and he has significant experience in commercializing rare disease drugs. He joins us from an outstanding career at Amgen, where he most recently served as Senior Vice President and General Manager for the U.S. Oncology Business. He previously worked at Alexion, where he led the development of ultra-orphan diseases therapies across 40 countries. I must say personally, but also we as a team, look forward to introducing Christophe upon his arrival next month in April. We look on the next slide, the 2020 building momentum slide. I provide a summary of 2020, which was an important momentum-building year for Orphazyme. We accomplished many goals against an extremely challenging backdrop due to the ongoing global pandemic. During 2020, we significantly advanced our pipeline in a product, arimoclomol, a first-class heat shock protein amplifier that we believe is a potential game changer in certain neurodegenerative rare diseases. We established a commercial organization in the U.S. based in Chicago, Illinois. We expand our commercial footprint here in Europe to support the potential drug launch. To secure the achievement of these aggressive goals during 2020, we chose to strengthen our balance sheet globally. We raised capital both in Europe and the U.S. In the U.S., we also did a U.S. public offering in Q3. In total, we raised more than 1.2 billion Danish kroner. Overall, we're very pleased with the progress in 2020. Importantly, at the base of the FDA approval, we are ready for the potential launch of arimoclomol for NPC in the United States. We're also very excited about the potential for our investigation products to provide therapeutic benefits in the ALS, IBM, and Gaucher communities. The next slide, which is the pipeline in the product. We are developing arimoclomol for several rare neurodegenerative diseases where limited or no suitable therapeutic options exist, and where we believe we can create high-value impact for those patient population and their families. Our pipeline is organized by the type of disease that we're pursuing. In green, we have the lysosomal storage diseases, which include NPC and Gaucher disease, and we believe there's a significant potential to develop arimoclomol in other lysosomal storage diseases also. In purple, we have the neuromuscular diseases where protein aggregation plays a central role. Protein aggregation may occur as a consequence of protein misfolding and is a hallmark in many neurodegenerative diseases. Our lead indication is NPC, an ultra-rare devastating genetic disorder that is a life-limiting condition with high unmet medical needs. We have reported the pivotal data and completed our investigation in the U.S., where we received the priority review with the PDUFA date of June 17th this year. We've also filed the Marketing Authorisation Application in Europe in November 2020. In Gaucher disease, our phase II data show clinical meaningful effect as early as six months regarding liver and spleen. we are excited about these data and look forward to providing an update on our Gaucher program in the coming months. In neuromuscular disease, we are looking forward to top-line data from our registrational trials in both IBM and ALS in the first half of this year. As a reminderWe have received both orphan and fast track designation for those two indications. With that overview of our pipeline and significant milestones we have achieved this year, and also anticipate this year, I'll then turn the call over to Molly Painter, who will review our commercialization strategy for arimoclomol. Molly? Thank you, Anders, I'm really excited to talk today about the enormous potential we have with arimoclomol. In the next slide, it'll go over our commercial overview. As you know, we're driving the program toward the market in both U.S. and Europe for four rare neurodegenerative diseases that Anders highlighted in his opening remarks. Our lead indication, Niemann-Pick disease Type C, or otherwise known as NPC. We estimate that there are about 2,000 patients in the U.S. and Europe, combined with a diagnosis rate around 40%-70%. NPC typically starts for many patients in their childhood, with around half of the patients today under 15 years old. Some children have very aggressive phenotypes and as you see very quickly, that they lose fine motor and cognitive skills and have difficulty swallowing. If they have a very aggressive phenotype, they are unlikely to survive beyond their teenage years, which is very devastating for families. There are currently no approved drugs for the treatment of NPC in the U.S. Beyond NPC, we're investigating arimoclomol for ALS, IBM, and Gaucher disease. We believe that ALS and IBM have the potential to be blockbuster market opportunities with about 50,000 patients for ALS and 40,000 patients for IBM. These are two indications with patient populations that are looking for answers and new treatment options. Currently, no approved therapies exist for IBM in the U.S. In the next slide, we talk about our established platform. We've worked very hard in 2020 to build our organization for the launch. As it stands today, we're ready for the potential launch of arimoclomol and NPC this year. We now have a fit-for-purpose commercial model that is scalable for NPC and additional indications. We have established our U.S. headquarters in Chicago, where I'm located, and we're putting together a strong multidisciplinary team in the U.S. with experience of more than 15 ultra-rare or rare disease launches. Our key account managers and national account directors are in place and ready. As part of this work, we made sure to keep our manufacturing and supply on track to be sure we meet anticipated demand, given our narrow window of approval. Our commercial organization is very strong across all these disciplines, and we're poised and ready to go upon approval. Until sub time, we will continue to enroll patients into our early access programs, now expanded to 12 sites in the U.S. We are actively engaging with U.S. payers to support patient access and have completed and scheduled presentations representing 77% of managed lives nationally and 55% of the total NPC community. This is all happening despite COVID-19, and much of this is work that is happening virtually. Outside the U.S., we've established EAPs in France and Germany, and we're building our European commercial infrastructure with the hiring of general managers in France, DACH Region, Spain, and the U.K. The next slide, we can talk about how we have talked about our commercial readiness. Let's talk about our global strategy and how we'll work to drive adoption upon approval. There's a three-pronged approach for the U.S., Europe, and the rest of the world. In the U.S., we expect for arimoclomol to be the first to market for NPC. Our research shows that payers will prioritize approved treatments as first-line therapy, which is very positive for us. In Europe, we expect arimoclomol to become an add-on therapy to miglustat, which is approved in the EU for NPC and is used off-label in the U.S. in about 40%-50% of patients. For the rest of the world, we plan to position arimoclomol as a first-line therapy in all territories, including U.S. and Europe, to hopefully transition patients who are currently on off-label therapies to arimoclomol. On this slide 10, which we'll transition to, I want to emphasize our exciting and near-term opportunity with arimoclomol to become standard of care for NPC. There's been a lot of movement in the NPC development space lately, with two key programs from large pharma being closed, which has caused tremendous disappointment to this well-informed patient community. In addition, it's worth noting that Zavesca became generic in 2020, which we believe With these recent events in the NPC development landscape, we are more confident than ever in our ability to deliver the first novel disease-modifying treatment to patients suffering with NPC, and we believe that arimoclomol is well positioned to become standard of care in this indication. In the next slide, I'll talk about one of the reasons that we feel so strongly that arimoclomol and NPC is the extensive physician survey work that we conducted and the outcomes and feedback that we've received. The KOL feedback suggests that patients would receive arimoclomol as an important part of their treatment regimen, whether it is first-line or add-on. This feedback is incredibly encouraging, not only for Orphazyme but for the NPC patients that we serve. I'd like to point out a specific quote here from Dr. Marc Patterson, who's the leading expert on NPC from the Mayo Clinic in the U.S., and a globally recognized neurological expert. He reinforces, "The NPC community that has been waiting for decades for an approved therapy for this disease and the availability of arimoclomol will offer an important treatment option to clinicians and great hope for affected individuals and their families." We are very pleased to have the support of these key opinion leaders as we prepare for a potential launch. Next slide, please. A key part of Orphazyme's approach since inception has been the emphasis on partnering and our strong relationships with scientific collaborators and patient advocacy groups. We have established relationships with specialist centers and are building our steering committees and advisory boards. For example, key opinion leaders and treatment teams to build out our medical education and congress programs. This slide really shows our partnerships with all four rare disease indications, including recently formed partnerships with CheckRare, a learning platform for healthcare professionals that is helping to educate on NPC. Our partners continue to inform our approach, elevate how we show up for patient communities we aim to serve, and remain a key component to our strategy in all four indications moving forward. In the next slide, I'll talk about how I'll close my remarks here and say I'm proud to announce the brand name for arimoclomol, which is MIPLYFFA. We've been working very hard on this campaign, and we look forward to sharing additional details when we are able. To reiterate, we have a huge opportunity to make a real difference in patients' lives. This work is very important to me. I've dedicated my career to helping people and their families living with rare diseases. I really am deeply moved by the patient community and their drive and their push for innovation. We have a tremendous responsibility to these patients, and I hope that we're able to deliver on their expectations. With that, I'll turn the call back over to Anders to review financials for 2020. Anders, the floor is yours. Thanks, Molly. During 2020, we laid the foundation for our future with investments in our commercial infrastructure and preparation for the potential launch of arimoclomol in NPC. As you heard Molly describe, we have established a fit for purpose commercial business, and we are now well-positioned to bring the product to the patients, if approved, and further maximize the potential of arimoclomol should it be successful in other indications. Let me go through the figures. Here you can see the figure as a summary for 2020. Our net loss widened from -DKK 337 to -DKK 633 for 2020, largely as a result of the increased operating expenses associated with our pre-launch activities and to support our growth. Our operating expenses amounted to DKK 609 million of the net loss in 2020. I'll go through this in more detail on the next slide. The additional 24 million in loss came from net financial expenses, mainly related to the increase in net foreign currency exchange losses of DKK 13 million, equivalent to $2.1 million, as well as the increase in interest expenses related to the loan agreement with Kreos Capital of DKK 6.7 million or equivalent to $1.1 million. Overall, the net loss per share was DKK 22.3 in the year-end of 2020, compared to DKK 16.9 in the previous year, -DKK 16.9. We conclude the year with DKK 727 million in cash, which is around $119 million. Our cash position was significantly boosted with the prior year as a result of the two successful financial raises during 2020, also including the U.S. listing. If you look on the next slide, the operating expenses. I would like to spend a bit more time on the operating expenses, which increased significantly during 2020 compared to the prior year, particularly D&A expense. D&A costs were driven by pre-launch activities and the build-up of our commercial infrastructure and global organization. We strengthened our U.S. and Switzerland-based commercial teams with 29 employees, and we increased the medical affairs activities, particularly for NPC. We further engaged with the scientific community through our communication and education programs. The administrative expenses rose also in 2020 compared to prior year, which was mainly due to legal, audit costs, investigations, and other external assistance, and also share-based compensation. In addition, we hired 20 employees in administration, finance, legal, and IT to support the growing organization as we have become global. Our R&D expenses for 2020 also rose compared to the prior year as we advanced our trials in IBM and ALS and also Gaucher disease and supported our registration activities in NPC. The increased cost was driven by the ramp-up of the three clinical pharmacology registration trials, increased clinical safety reporting activities in ongoing trials, and the expansion of our R&D by 12 employees. Next slide, please. That's our financial outlook. As we said before, we expect 2021 to be a transformational year for Orphazyme with the potential approval of our first product for NPC and the readout of two late-stage trials in the first half of this year. The outcome and the time of these events are clearly key factors in driving how we think about 2021 and our outlook. We expect our operating expenses for 2021 to be in a range of DKK 800 million- DKK 850 million. This is driven by continued investment in R&D to support the advancement and completion of our multiple clinical trials in IBM and ALS, including data readouts and preparation for filing if successful. We anticipate continuing to invest in commercial infrastructure in the U.S. and Europe to support product launches if arimoclomol is approved. We cannot speculate on regulatory outcomes, Orphazyme, we are preparing for success and well-positioned to launch arimoclomol within a narrow window of a potential approval. Our revenue forecast currently anticipate a gradual increase in sales from arimoclomol during the second half, in the range of DKK 60 million-DKK 120 million, or equivalent to around $10 million-$20 million by year-end. This forecast also includes small amount of potential income from maintenance and sales in other countries. Importantly, our outlook for 2021 assumes that we are awarded the priority review voucher from the FDA if arimoclomol is approved, and that's if we can monetize the priority review voucher. The value of these vouchers during 2020 was between DKK 95 million- DKK 110 million. We expect our operating expenses to total between DKK 800 million- DKK 850 million and to end the year with in excess of DKK 350 million in cash or equivalent to around $57 million. We believe we have a strong financial position and balance sheet to take us through the commercialization in NPC and additional indications, while also continuing to build a leading rare disease company. Next slide, please. Before getting to Q&A, let me review what's coming up for Orphazyme in this transformational year ahead of us. In 2021, we are focusing on getting arimoclomol to the NPC patients with early access programs and also preparation for launch. With commercial rollout both in U.S. and Europe, we will also explore possibilities for partnerships in the rest of the world. We have completed the NDA submission in the U.S. for arimoclomol in NPC, and our PDUFA date is June 17. We also submitted the Marketing Authorisation Application in EU in November last year, and we anticipate the potential approval in Europe in the fourth quarter of this year. Beyond NPC, we expect top-line data from ALS and IBM trials in the first half of this year, and a decision on developing arimoclomol in Gaucher disease. As you've heard today, it is a very exciting time for Orphazyme, with a lot happening for the company and importantly for the patients with these devastating diseases. Now, I would like to hand back the call to the moderator for Q&A. Bernard? Thank you. Ladies and gentlemen, we'll now begin the question and answer session. Your first question comes on the line of Thomas Bowers from Danske Bank. Please ask your question. Yes. Thank you very much. A couple of questions from me. If we just dive into the full-year guidance, 2021 guidance. I'm just wondering how much impact should we expect from the, you could say the commercial preparations in both the ALS and IBM trials, if they, of course, read out positive? In addition to that, I'm just wondering if you actually have the capacity internally to submit two NDA filings in parallel. Could you maybe give us some guidance on the expected filing timelines to submit the NDAs after we have the top-line readout here in the second quarter? I have a couple of pipeline questions. Maybe we can just kick off with the financial stuff here. Thank you, Thomas. It's a good question. What we have included in the outlook is, as I said, the filing cost for ALS and IBM if they are positive, and also as you address internal capacity and so on. It's something that we're working on, finding a solution on, but I'll let Thomas Blaettler go through the filing process. On the cost side, it's very much depending on data, what extra cost we can see coming in in 2021. If it's very strong data in ALS, that's one situation, if it's strong data in IBM, it's another one because of difference between the indications. If both combined is positive, then of course, we will have to engage with patient organizations on the medical fair side and so on. We will have a ramp-up in cost on certain areas. Put a number now before we have the data, that I'm not comfortable with, Thomas. Blaettler, would you answer our ability to file two products simultaneously and maybe also if you have any, let's say, desire to talk about timing? Blaettler. Yes. Thank you, Anders. Thomas, obviously, filing an NDA or an MAA does take a lot of resources, so you rightfully ask that question. We have two distinct teams, one working on ALS and one on IBM. We are looking to take into account the resources needed. Obviously, in a scenario where both trials lent themselves for submission of a file, we will have to look at the data, look which of the indications would have to take priority. That will be based on both an assessment of the likelihood of success, but also on the unmet needs. We will include additional resources to advance the filings as quickly as possible. You should anticipate that it's not an exactly parallel filing. There will be a certain sequence in the filing, with the first filing intended still in this year. Okay. Thank you. If I can just ask on the ALS trial, just in regards to the open-label trial, you managed to recruit 120 patients, or you can say about half of what you had in the phase III, combined with the historical data, with an average survival of 18 months. I'm just wondering if now we have some where it's been a few months here, anything that makes you maybe a little bit more upbeat or downbeat based on the number of patients, based on other factors like dropout rates or whatever you see among these patients that could sort of reflect the number of patients who were able to recruit in the open-label trial? I have a last question also just on the EAP. I think Marty said you now have 12 centers here in your prepared remarks. I'm just wondering how many NPC patients is actually by now on the early access program, and do you have any sort of predictions on the expected number that you aim for here now in connection with, you would say, mid-year launch, maybe, now that we at least have the VTS-270 program from Mallinckrodt's now being terminated. I'm just wondering whether you're seeing a big uptake of patients coming to this early access with that program being shut down. Thank you. Okay. Yeah, Blaettler, I would like you to talk about the dropout on ALS, and then Molly Painter, if you could comment on where we are on the EAP in the U.S. and the expectation for further enrollment. First, as a reminder, we are still blinded to treatment allocations, so I will refrain from speculating on the outcome of this file. Having 120 patients rolling over from the randomized file into the open label is absolutely within the frame that I expected. Bear in mind, we have had a number of patients, a good fraction of the patients who have met their survival endpoint, so have died. We have a number of patients who, as expected, have discontinued from the file. All the numbers we have to date on a blinded level are well within our expectations. Thank you. On the EAP? Yeah, on the EAP, I'll take that question if okay. We have, I believe now, to your point, we've had increased interest, obviously with some of the market events taking place, but just around 35 patients enrolled with a split towards children and adults skewing to the side of more adult patients, but a fair amount of children have enrolled as of late. We anticipate that to continue to grow as there's a significant need for these folks. All right, great. Thank you very much. Thanks, Thomas. Your next question comes on the line of Anders from Redeye. Please ask your question. Good afternoon. Can you guys hear me? Yes. Anders, I'm trying to get my head around the outlook as well. Am I correct that there is a discrepancy there between what you guide for an operating loss and a cash position? And is there, for instance, something that lies behind that you see a buildup of CapEx and/or networking capital for the current year? It's a very insightful question here. Yes, when the product is potentially approved, then whatever you produce as product, you put on the balance sheet. There might be some cash flow investments or some investments in products that is not on the P&L. I would say that's the most direct. That's the biggest change that would take place when we get the approval, potentially. Okay. Build up our working capital, basically. Yes. Correct. Yeah. Good. Okay. In terms of the early pipeline, can we expect any anticipated milestones for the current year in terms of preclinical and/or research activities? If there will be anything, that will be in the second half. It's an early-stage program. We haven't defined any milestones for the second half yet, but it's a possibility on it. Okay. Thank you. Your next question is on the line. That's Tazeen Ahmad from Bank of America. Please ask your question. Good morning. Can you hear me? Yes. Okay, perfect. Can I ask a question on your upcoming data for ALS? Specifically, what type of information should we expect to see at the top line? Is it your belief that you would be able to apply for approval based on this specific study if it is, in fact, positive? The second question is on the competitive landscape in ALS. There are quite a few companies that are trying to explore this indication. One that I'd specifically like your thoughts on is from a company called Amylyx, which last year, I believe, or recently, produced statistically significant positive data for their study. I wanted to know how you think about how your program could differentiate potentially from this one, and just noting that the potential for ALS is quite large. There could be room for many players. Just wanted to get your thoughts in general about where you think your program in ALS could be differentiated further. Thank you. Thank you. Peter, would you start trying to answer what you can cover here? I think it's a very good list of questions. Yes. I tried to chuck it down, so I hope I remember everything. Otherwise, you may have- Sorry Questions. Well, first, what is the information we expect from the top-line results? We will have 18 months, which is the time point of the primary assessment. We'll have 18 months data on the primary endpoint, the CAFS, which is the Combined Assessment of Function and Survival, on both components, which are also secondary endpoints, so ALSFRS-R and survival. We will also have information on the pulmonary function and additional secondary endpoints, and we do anticipate to have information on biomarkers. Here, the greatest interest is, of course, with the neurofilament light chain, both in CSF and in plasma. Also, of course, we will have the safety tolerability information. You asked about Amylyx and the Amylyx phase II trial. Maybe just answer the approvability, if the data is strong enough. Our assumption, that is also based on a Type C meeting with FDA and scientific advice with EMA, is that this trial supports an approval. It's positive both in the U.S. and EU, of course, we would also then have ambitions to go beyond those regions. Okay. The trial was specifically designed also to address both needs from FDA and EMA with this regard. This actually does take me to the comparison to the Amylyx program, which was a six-month randomized placebo-controlled trial followed by an open label extension. The primary endpoint in the Amylyx trial was the ALSFRS-R at six months. They have since reported also an advantage of longer survival with patients who were initially randomized to the active drug versus placebo. If you now want to compare our phase III trial, that's an 18-month trial. If positive, we'll demonstrate an effect both on survival and functioning, and we will have 18 months of randomized blinded data, which of course gives you a longer time span to understand the effect of the drug, both efficacy-wise and also from a safety and tolerability perspective. In addition to that, we also have an open label extension, as you also heard just earlier. We will generate additional data in patients who start treatment late, and we'll even further understand the long-term benefits of treatment with arimoclomol. arimoclomol is amplifying the heat shock response, the natural stress response. With that, arimoclomol would lend itself to combination with a range of other treatments. We do not conceive other treatments in development or being approved as being in competition with arimoclomol. In our view, the future treatment of patients with ALS will be a combination treatment that combines the different treatments and hopefully tailors the treatments to the actual patients along the lines of personalized medicine. Here again, the broad mechanism of action of arimoclomol lends itself to be used as a component, as a pillar of such combination treatment. Yeah. Thank you so much. Thank you, Thomas. Thank you. Your next question comes on the line of Yatin Suneja from Guggenheim Securities. Please ask your question. Hey, guys. Can you hear me? Yes. Mm-hmm. Perfect. Just a couple questions from me. First one is on the revenue guidance that you provided for DKK 10 million-DKK 20 million. Can you maybe talk about some of the push and pulls? How should we think about the price? What about the range of patients that you assume for this level of guidance? Yeah. It's a very good question, Yatin Suneja. I won't dare to talk about price before we get the approval, potentially. What we have built the assumptions on is, as Molly Painter has described, the number of EAP patients that are in, but also could come in until we get the approval. Then, of course, the naive patients in the U.S. that are not currently on treatment. It's a combination. The pricing is too specific for me to go into detail. Okay. Just one more question on the EAP. With regard to the Mallinckrodt drug which had a recent failure, can you remind us how big was their EAP and what your expectations are for transitioning those patients maybe into your program, and what was the split between U.S. and Europe for their program, if you have that information? Thank you. Yeah. We don't have the specific information. We know that the trial was done globally and then also in Europe and the U.S. Else we don't have any insight. Of course, Biocom patients asking us that their program will stop having patients being treated in October of this year. I don't know the specifics. Okay. Thank you so much. No problem. Thank you. Thank you. Your next question comes on the line of Ritu Baral from Cowen. Please ask your question. Good morning, guys. Thanks for taking the question. I wanted to ask about any anticipated safety monitoring requirements that you guys might have in the label and how that might impact either how your patient hub will run and what it will need to keep track of, and ultimately, the launch. I have a follow-up. Okay. Thank you, Ritu. Blaettler, would you start if you're there? Yeah. I must say, we have not had any concrete indication yet from the regulators on obligations for safety monitoring following an approval. I would actually like to refrain from speculating here. Fair enough. A question for Molly. Can you remind us again how the patient hub is set up? Are those contract services or are those in-house people? In the event of a potential early approval, are they ready to go right now? Yeah. They're ready to go right now. We are working with an outside source to set up our, what some would deem in this business, call it a hub or a patient services model, for each prescription to come through and be handled on a patient-by-patient basis. Great. Last question. Anders, as you think about the ALS data and the IBM data coming in and the differences in market size, I guess, how are you thinking about potentially changing the price? I know in answer to Yatin's question, you don't want to give specific price for NPC. What are the tools that you might be able to use to, I guess, amend the price to? Yeah reflect the updated population? Yeah, it's a good question also because we might get the data before we get the approval. Of course, that might also influence the positioning also on the price because. If we have clear strong data, that's one scenario. There's a lot of aspects here, but specifically on the pricing, so we have made some assumptions on, of course, NPC alone, and then we are also doing some discussions on what to do if strong data comes in ALS, because as the market is so much bigger, the number of patients and also new patients coming into the disease every year in the U.S. might be 5,000 patients. It's a very big market potentially. Molly, I think this is more into your area. You've been doing a lot of thinking of this. Maybe you can provide a bit of color. I think you said most of it. We're scenario planning for various different permutations and doing it based off of analogs and where the market is today, so we can do so responsibly and do it the right way. We're thinking through every different scenario. Got it. Thanks for taking the question, Molly. Under review. Yeah. Thank you. Thanks. Once again, for any questions, please press star one on your telephone keypad. There are no further questions at this time. Please continue. Thank you very much. I will just close off by saying that I appreciate very much your participation in today's call, and we look forward to continue to provide you updates on our progress, especially the first half of this year. You can see all the activities that is going on. We will continue to provide information on those activities and also potential approval in the second half in the EU. You will hear a lot from us this year. Thank you very much.